Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study
Introduction: Although pretreatment autoantibodies have been associated with immune-related adverse events (irAEs) and immune checkpoint inhibitor treatment efficacy in some types of cancer, their importance has not been evaluated in patients with SCLC. Methods: A multicenter prospective observation...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364323001510 |
| _version_ | 1827577267920830464 |
|---|---|
| author | Yuki Sato, MD Satoru Fujiwara, MD Akito Hata, MD Yoko Kida, MD Takahiro Masuda, MD Hisanori Amimoto, MD Hirotaka Matsumoto, MD Kotoko Miyoshi, MD Kojiro Otsuka, MD, PhD Keisuke Tomii, MD, PhD |
| author_facet | Yuki Sato, MD Satoru Fujiwara, MD Akito Hata, MD Yoko Kida, MD Takahiro Masuda, MD Hisanori Amimoto, MD Hirotaka Matsumoto, MD Kotoko Miyoshi, MD Kojiro Otsuka, MD, PhD Keisuke Tomii, MD, PhD |
| author_sort | Yuki Sato, MD |
| collection | DOAJ |
| description | Introduction: Although pretreatment autoantibodies have been associated with immune-related adverse events (irAEs) and immune checkpoint inhibitor treatment efficacy in some types of cancer, their importance has not been evaluated in patients with SCLC. Methods: A multicenter prospective observational study was conducted on a total of 52 patients with extensive-disease SCLC who received immune checkpoint inhibitors in combination with chemotherapy as the first-line treatment at either of the six participating centers in Japan. Pretreatment serum samples were collected and analyzed for autoantibodies (rheumatoid factor, antinuclear antibodies, and antithyroid). Moreover, 12 antineuronal antibodies (AMPH, CV2, PNMA2, Ri, Yo, Hu, Recoverin, SOX1, Titin, Zic4, GAD65, and Tr) were analyzed using immunoblot assays. The primary end point was the incidence of irAEs with or without autoantibodies. The secondary end points were progression-free survival (PFS) and overall survival (OS) on the basis of the presence or absence of autoantibodies. Results: PFS and OS were 4.4 and 25.3 months, respectively. Autoantibodies (rheumatoid factor, antinuclear antibodies, and antithyroid antibodies) were detected in 29 patients (56%). In total, irAEs were observed in 18 patients (35%); irAE incidence was 48% in the autoantibody-positive group and 17% in the autoantibody-negative group (p = 0.039). There was no difference in PFS or OS between patients with and without autoantibodies (4.4 mo versus 4.6 mo, p = 0.36; 15.3 mo versus 18.2 mo, p = 0.36). Antineuronal antibodies were detected in 16 patients (31%). However, the development of neurologic irAEs was not observed in both groups. Conclusions: Vigilance is required against the development of irAEs in pretreatment antibody-positive patients. |
| first_indexed | 2024-03-08T21:24:29Z |
| format | Article |
| id | doaj.art-afe89a5eb7694938a99941a50b7a87ea |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-03-08T21:24:29Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-afe89a5eb7694938a99941a50b7a87ea2023-12-21T07:37:27ZengElsevierJTO Clinical and Research Reports2666-36432023-12-01412100608Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational StudyYuki Sato, MD0Satoru Fujiwara, MD1Akito Hata, MD2Yoko Kida, MD3Takahiro Masuda, MD4Hisanori Amimoto, MD5Hirotaka Matsumoto, MD6Kotoko Miyoshi, MD7Kojiro Otsuka, MD, PhD8Keisuke Tomii, MD, PhD9Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan; Corresponding author. Address for correspondence: Yuki Sato, MD, Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-minamimachi, Chuo-ku, 650-0047, Kobe, Japan.Department of Neurology, Kobe City Medical Center General Hospital, Kobe, JapanDepartment of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Kobe, JapanDepartment of Respiratory Medicine, Kobe City Nishi-Kobe Medical Center, Kobe, JapanDepartment of Respiratory Medicine, Kobe City Nishi-Kobe Medical Center, Kobe, JapanDepartment of Respiratory Medicine, Kobe City Medical Center West Hospital, Kobe, JapanDepartment of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, JapanDepartment of Respiratory Medicine, Shinko Hospital, Kobe, JapanDepartment of Respiratory Medicine, Shinko Hospital, Kobe, JapanDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, JapanIntroduction: Although pretreatment autoantibodies have been associated with immune-related adverse events (irAEs) and immune checkpoint inhibitor treatment efficacy in some types of cancer, their importance has not been evaluated in patients with SCLC. Methods: A multicenter prospective observational study was conducted on a total of 52 patients with extensive-disease SCLC who received immune checkpoint inhibitors in combination with chemotherapy as the first-line treatment at either of the six participating centers in Japan. Pretreatment serum samples were collected and analyzed for autoantibodies (rheumatoid factor, antinuclear antibodies, and antithyroid). Moreover, 12 antineuronal antibodies (AMPH, CV2, PNMA2, Ri, Yo, Hu, Recoverin, SOX1, Titin, Zic4, GAD65, and Tr) were analyzed using immunoblot assays. The primary end point was the incidence of irAEs with or without autoantibodies. The secondary end points were progression-free survival (PFS) and overall survival (OS) on the basis of the presence or absence of autoantibodies. Results: PFS and OS were 4.4 and 25.3 months, respectively. Autoantibodies (rheumatoid factor, antinuclear antibodies, and antithyroid antibodies) were detected in 29 patients (56%). In total, irAEs were observed in 18 patients (35%); irAE incidence was 48% in the autoantibody-positive group and 17% in the autoantibody-negative group (p = 0.039). There was no difference in PFS or OS between patients with and without autoantibodies (4.4 mo versus 4.6 mo, p = 0.36; 15.3 mo versus 18.2 mo, p = 0.36). Antineuronal antibodies were detected in 16 patients (31%). However, the development of neurologic irAEs was not observed in both groups. Conclusions: Vigilance is required against the development of irAEs in pretreatment antibody-positive patients.http://www.sciencedirect.com/science/article/pii/S2666364323001510Small-cell lung cancerImmune-related adverse eventAutoantibodyParaneoplastic autoantibodyParaneoplastic neurologic syndrome |
| spellingShingle | Yuki Sato, MD Satoru Fujiwara, MD Akito Hata, MD Yoko Kida, MD Takahiro Masuda, MD Hisanori Amimoto, MD Hirotaka Matsumoto, MD Kotoko Miyoshi, MD Kojiro Otsuka, MD, PhD Keisuke Tomii, MD, PhD Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study JTO Clinical and Research Reports Small-cell lung cancer Immune-related adverse event Autoantibody Paraneoplastic autoantibody Paraneoplastic neurologic syndrome |
| title | Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study |
| title_full | Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study |
| title_fullStr | Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study |
| title_full_unstemmed | Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study |
| title_short | Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study |
| title_sort | clinical impact of pre existing autoantibodies in patients with sclc treated with immune checkpoint inhibitor a multicenter prospective observational study |
| topic | Small-cell lung cancer Immune-related adverse event Autoantibody Paraneoplastic autoantibody Paraneoplastic neurologic syndrome |
| url | http://www.sciencedirect.com/science/article/pii/S2666364323001510 |
| work_keys_str_mv | AT yukisatomd clinicalimpactofpreexistingautoantibodiesinpatientswithsclctreatedwithimmunecheckpointinhibitoramulticenterprospectiveobservationalstudy AT satorufujiwaramd clinicalimpactofpreexistingautoantibodiesinpatientswithsclctreatedwithimmunecheckpointinhibitoramulticenterprospectiveobservationalstudy AT akitohatamd clinicalimpactofpreexistingautoantibodiesinpatientswithsclctreatedwithimmunecheckpointinhibitoramulticenterprospectiveobservationalstudy AT yokokidamd clinicalimpactofpreexistingautoantibodiesinpatientswithsclctreatedwithimmunecheckpointinhibitoramulticenterprospectiveobservationalstudy AT takahiromasudamd clinicalimpactofpreexistingautoantibodiesinpatientswithsclctreatedwithimmunecheckpointinhibitoramulticenterprospectiveobservationalstudy AT hisanoriamimotomd clinicalimpactofpreexistingautoantibodiesinpatientswithsclctreatedwithimmunecheckpointinhibitoramulticenterprospectiveobservationalstudy AT hirotakamatsumotomd clinicalimpactofpreexistingautoantibodiesinpatientswithsclctreatedwithimmunecheckpointinhibitoramulticenterprospectiveobservationalstudy AT kotokomiyoshimd clinicalimpactofpreexistingautoantibodiesinpatientswithsclctreatedwithimmunecheckpointinhibitoramulticenterprospectiveobservationalstudy AT kojirootsukamdphd clinicalimpactofpreexistingautoantibodiesinpatientswithsclctreatedwithimmunecheckpointinhibitoramulticenterprospectiveobservationalstudy AT keisuketomiimdphd clinicalimpactofpreexistingautoantibodiesinpatientswithsclctreatedwithimmunecheckpointinhibitoramulticenterprospectiveobservationalstudy |